Clinical Trial Search

Primary: Efficacy Endpoint: First Occurrence of Reverse Transcription-polymerase Chain Reaction (RT-PCR) Confirmed Influenza, Due to Any Influenza Type A and/or B Virus…

Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607

Primary: Clinical Global Impression of Improvement Scale (CGI-I) — 8; 20; 7; 12 Participants

Primary: Number of Participants With Adverse Events and/or Dose Limiting Toxicities of Sintilimab in Combination With SBRT and LDRT — 0; 5; 1; 6 Participants

Primary: New Participation in MOVE! (Among Women Aged 65 and Older) — 1.09 Odds Ratio — p=.003

Primary: Partial Pressure CO2 (pCO2) : Data From the Crossover Phase of the Study — 38.7; 36.8 mm Hg

Primary: Number of Participants Who Experienced of Intracranial Hemorrhage in Total Follow-up Period — 2; 25 Participants

Primary: Test Device's Blood Pressure of Resting Condition — -1.55; -0.02; -1.6; -0.0 mmHg

Primary: Change in the Bent Knee Fall Out Test — 3.9 cm

Primary: Number of Patients 65 and Older With New Documentation of Any Advance Directive in the Electronic Health Record (EHR) — 2190; 2130; 255; 409 Participants

Primary: Primary Effectiveness Endpoint - Clot Removal Grade From Pre-JETi to Post-JETi - Core Lab Assessed - Per Vessel Analysis — 36; 41; 52; 93 Vessels

Primary: Progression-Free Survival (PFS) — 6.44 months

Primary: Change From Baseline in Child Behavior Problems (Parent Report) — 73.60; 77.95; 71.49; 71.69 score on a scale — p=.361

Primary: Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state) — -0.10; 0.57; -0.04 units on a scale

Primary: Right Side Lying Post NST (3) — 113.67; 108.16; 112.80 mmHg